MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$1,244M
Net Income
-$71M
Net Profit Margin
-5.71%
EPS
-$0.2
Unit: Million (M) dollars
Revenue Breakdown
    • Product
    • Product And Service Other
Revenue Breakdown
    • Vision Care
    • Pharmaceuticals
    • Surgical

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
1,244 1,405 1,281 1,278
Cost of goods sold (excluding amortization and impairments of intangible assets) and cost of other revenues-Product
482 533* 509 523
Cost of goods sold (excluding amortization and impairments of intangible assets) and cost of other revenues-Product And Service Other
1 1* 1 2
Selling, general and administrative (note 4)
544 564 528 579
Research and development
101 94 95 96
Amortization of intangible assets
57 56 68 67
Other expense, net
-26 -46 15 -22
Total expenses
1,211 1,293 1,186 1,289
Operating income (loss)
33 112 95 -11
Interest income
4 3 3 3
Interest expense
97 98 101 128
Gain on extinguishment of debt
-1 0 3 -9
Foreign exchange and other
-3 -4 -3 -2
Gain before provision for income taxes
-64 13 -3 -147
Expected provision for income taxes at canadian statutory rate
NaN 43* NaN NaN
Domestic provincial and local income taxes, net of federal (national) income tax effect
NaN 0* NaN NaN
Foreign tax rate differences-US
NaN -1* NaN NaN
Effects of cross-border taxes-US
NaN 1* NaN NaN
Research & development tax credits-US
NaN 2* NaN NaN
Contingent consideration fair value adjustments-US
NaN -1* NaN NaN
Intercompany profit in ending inventory-US
NaN 1* NaN NaN
Other-US
NaN 1* NaN NaN
Foreign tax rate differences-IE
NaN 12* NaN NaN
Change in valuation allowance-IE
NaN 3* NaN NaN
Disallowed interest-IE
NaN 4* NaN NaN
Capital loss on sale of assets-IE
NaN -2* NaN NaN
Foreign exchange impact-IE
NaN 1* NaN NaN
Intercompany profit in ending inventory-IE
NaN -4* NaN NaN
Other-IE
NaN 0* NaN NaN
Change in valuation allowance-NL
NaN 1* NaN NaN
Other-NL
NaN 0* NaN NaN
Foreign tax rate differences-DE
NaN -2* NaN NaN
Other-DE
NaN 1* NaN NaN
Foreign tax rate differences-Foreign Tax Jurisdiction Other
NaN 2* NaN NaN
Effect of changes in tax laws or rates enacted in the current period
NaN 0* NaN NaN
Effects of cross-border taxes-CA
NaN 1* NaN NaN
Tax credits
NaN 0* NaN NaN
Change in valuation allowance-CA
NaN 4* NaN NaN
Non-deductible amount of share-based compensation
NaN 4* NaN NaN
Disallowed interest-CA
NaN 1* NaN NaN
Change in uncertain tax positions
NaN 0* NaN NaN
Foreign exchange impact-CA
NaN 6* NaN NaN
Other-CA
NaN 0* NaN NaN
Provision for income taxes
6 71 22 -89
Net loss
-70 -58 -25 -58
Net income attributable to noncontrolling interest
1 0 3 4
Net loss attributable to bausch + lomb corporation
-71 -58 -28 -62
Basic EPS
-0.2 -0.164 -0.08 -0.18
Diluted EPS
-0.2 -0.164 -0.08 -0.18
Basic Average Shares
355,200,000 354,500,000 354,200,000 353,700,000
Diluted Average Shares
355,200,000 354,500,000 354,200,000 353,700,000
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Vision Care$708M Pharmaceuticals$304M (14.29%↑ Y/Y)Surgical$227M (6.57%↑ Y/Y)Vision Care$3M (50.00%↑ Y/Y)Surgical$1M (0.00%↑ Y/Y)Pharmaceuticals$1M (0.00%↑ Y/Y)Net lossattributable to bausch + lomb...-$71M (66.51%↑ Y/Y)Product$1,239M (9.36%↑ Y/Y)Product And ServiceOther$5M Net loss-$70M (66.82%↑ Y/Y)Net incomeattributable to...$1M (0.00%↑ Y/Y)Total revenues$1,244M (9.41%↑ Y/Y)Gain beforeprovision for income taxes-$64M (64.44%↑ Y/Y)Provision for income taxes$6M (-80.65%↓ Y/Y)Operating income (loss)$33M (139.76%↑ Y/Y)Interest income$4M (33.33%↑ Y/Y)Total expenses$1,211M (-0.74%↓ Y/Y)Interest expense$97M (3.19%↑ Y/Y)Foreign exchange andother-$3M (50.00%↑ Y/Y)Gain onextinguishment of debt-$1M Selling, general andadministrative (note 4)$544M (-3.37%↓ Y/Y)Cost of goods sold(excluding amortization...$482M Research and development$101M (17.44%↑ Y/Y)Amortization of intangibleassets$57M (-14.93%↓ Y/Y)Other expense, net-$26M (-18.18%↓ Y/Y)Cost of goods sold(excluding amortization...$1M

Bausch & Lomb Corp (BLCO)

Bausch & Lomb Corp (BLCO)